Evolocumab therapy demonstrates long-term efficacy, safety and tolerability in patients with homozygous (HoFH) and severe heterozygous familial hypercholesterolaemia (HeFH), reducing plasma low-density lipoprotein cholesterol (LDL-C) as well as the need for LDL apheresis, a study has shown.
Lim Jack Shen, assistant general manager of business development at Berjaya Corporation, talks about his experiences with developing MyTigas Alliance, a collaboration of independent community pharmacies for providing group healthcare services.
Use of virtual reality (VR) helps reduce pain during childbirth, and may present a novel nonpharmacologic approach to controlling labour pain, suggests a study presented at SMFM 2020 Annual Pregnancy Meeting in Grapevine, Texas, US.
Many children in Singapore may not be vaccinated according to the national recommended immunization schedule, with maternal age, ethnicity, household income, and number of siblings among the factors influencing non-adherence, according to findings from the GUSTO* study.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
Maintenance therapy with the anti-PD-L1* checkpoint inhibitor avelumab failed to show superior overall survival (OS) compared with continuation chemotherapy (CT) following first-line** (1L) CT in patients with previously untreated, unresectable, and locally advanced/metastatic HER2-negative gastric or gastroesophageal cancer (GC/GEJC), according to the results of the phase III JAVELIN Gastric 100 trial presented at ASCO GI 2020.
Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.
New drug applications approved by US FDA as of 01 - 15 February 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The combination of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, with hormonal add-back therapy significantly reduces heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to two phase III studies.
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).